Logo image of CATX

PERSPECTIVE THERAPEUTICS INC (CATX) Stock Fundamental Analysis

NYSEARCA:CATX - NYSE Arca - US46489V3024 - Common Stock - Currency: USD

2.39  -0.12 (-4.78%)

After market: 2.5187 +0.13 (+5.38%)

Fundamental Rating

2

Overall CATX gets a fundamental rating of 2 out of 10. We evaluated CATX against 561 industry peers in the Biotechnology industry. The financial health of CATX is average, but there are quite some concerns on its profitability. CATX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CATX has reported negative net income.
In the past year CATX has reported a negative cash flow from operations.
In the past 5 years CATX always reported negative net income.
CATX had a negative operating cash flow in each of the past 5 years.
CATX Yearly Net Income VS EBIT VS OCF VS FCFCATX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

CATX has a better Return On Assets (-23.24%) than 75.22% of its industry peers.
The Return On Equity of CATX (-27.27%) is better than 79.86% of its industry peers.
Industry RankSector Rank
ROA -23.24%
ROE -27.27%
ROIC N/A
ROA(3y)-27.34%
ROA(5y)-25.32%
ROE(3y)-33.67%
ROE(5y)-33.3%
ROIC(3y)N/A
ROIC(5y)N/A
CATX Yearly ROA, ROE, ROICCATX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CATX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CATX Yearly Profit, Operating, Gross MarginsCATX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

5

2. Health

2.1 Basic Checks

CATX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CATX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for CATX has been increased compared to 5 years ago.
The debt/assets ratio for CATX has been reduced compared to a year ago.
CATX Yearly Shares OutstandingCATX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
CATX Yearly Total Debt VS Total AssetsCATX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of 1.37, we must say that CATX is in the distress zone and has some risk of bankruptcy.
CATX's Altman-Z score of 1.37 is fine compared to the rest of the industry. CATX outperforms 70.59% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that CATX is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.01, CATX perfoms like the industry average, outperforming 44.03% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 1.37
ROIC/WACCN/A
WACC10%
CATX Yearly LT Debt VS Equity VS FCFCATX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

CATX has a Current Ratio of 12.68. This indicates that CATX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 12.68, CATX belongs to the best of the industry, outperforming 85.20% of the companies in the same industry.
CATX has a Quick Ratio of 12.68. This indicates that CATX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CATX (12.68) is better than 85.20% of its industry peers.
Industry RankSector Rank
Current Ratio 12.68
Quick Ratio 12.68
CATX Yearly Current Assets VS Current LiabilitesCATX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

CATX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.44%, which is quite impressive.
Looking at the last year, CATX shows a very negative growth in Revenue. The Revenue has decreased by -81.28% in the last year.
Measured over the past years, CATX shows a very negative growth in Revenue. The Revenue has been decreasing by -27.60% on average per year.
EPS 1Y (TTM)44.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.59%
Revenue 1Y (TTM)-81.28%
Revenue growth 3Y-47.5%
Revenue growth 5Y-27.6%
Sales Q2Q%-88.5%

3.2 Future

CATX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -10.39% yearly.
CATX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 183.99% yearly.
EPS Next Y-55.15%
EPS Next 2Y-33.42%
EPS Next 3Y-23.93%
EPS Next 5Y-10.39%
Revenue Next Year-50.39%
Revenue Next 2Y-36.56%
Revenue Next 3Y82.38%
Revenue Next 5Y183.99%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CATX Yearly Revenue VS EstimatesCATX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
CATX Yearly EPS VS EstimatesCATX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CATX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CATX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CATX Price Earnings VS Forward Price EarningsCATX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CATX Per share dataCATX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

CATX's earnings are expected to decrease with -23.93% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-33.42%
EPS Next 3Y-23.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CATX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PERSPECTIVE THERAPEUTICS INC

NYSEARCA:CATX (5/23/2025, 9:17:58 PM)

After market: 2.5187 +0.13 (+5.38%)

2.39

-0.12 (-4.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)N/A N/A
Inst Owners70.33%
Inst Owner Change-3.56%
Ins Owners3.05%
Ins Owner Change0.13%
Market Cap177.41M
Analysts81.05
Price Target14.2 (494.14%)
Short Float %8.93%
Short Ratio7.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.74%
Min EPS beat(2)3.49%
Max EPS beat(2)7.98%
EPS beat(4)4
Avg EPS beat(4)10.85%
Min EPS beat(4)3.49%
Max EPS beat(4)15.97%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)15.46%
Min Revenue beat(2)-6.05%
Max Revenue beat(2)36.98%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.65%
PT rev (3m)-15.62%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-5.05%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.07%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-28.21%
Revenue NY rev (1m)-9.18%
Revenue NY rev (3m)-9.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 121.72
P/FCF N/A
P/OCF N/A
P/B 0.61
P/tB 0.74
EV/EBITDA N/A
EPS(TTM)-0.84
EYN/A
EPS(NY)-1.3
Fwd EYN/A
FCF(TTM)-0.98
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0.02
BVpS3.93
TBVpS3.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.24%
ROE -27.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.34%
ROA(5y)-25.32%
ROE(3y)-33.67%
ROE(5y)-33.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2362.79%
Cap/Sales 3747.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.68
Quick Ratio 12.68
Altman-Z 1.37
F-Score4
WACC10%
ROIC/WACCN/A
Cap/Depr(3y)856.63%
Cap/Depr(5y)587.66%
Cap/Sales(3y)1275.31%
Cap/Sales(5y)766.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.59%
EPS Next Y-55.15%
EPS Next 2Y-33.42%
EPS Next 3Y-23.93%
EPS Next 5Y-10.39%
Revenue 1Y (TTM)-81.28%
Revenue growth 3Y-47.5%
Revenue growth 5Y-27.6%
Sales Q2Q%-88.5%
Revenue Next Year-50.39%
Revenue Next 2Y-36.56%
Revenue Next 3Y82.38%
Revenue Next 5Y183.99%
EBIT growth 1Y9.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-30.19%
EBIT Next 3Y-20.9%
EBIT Next 5YN/A
FCF growth 1Y-91.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.44%
OCF growth 3YN/A
OCF growth 5YN/A